GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » ROC (Joel Greenblatt) %

Indaptus Therapeutics (Indaptus Therapeutics) ROC (Joel Greenblatt) % : -9,037.84% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Indaptus Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9,037.84%.

The historical rank and industry rank for Indaptus Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

INDP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -359900   Med: -12293.22   Max: -8883.91
Current: -9038.63

During the past 4 years, Indaptus Therapeutics's highest ROC (Joel Greenblatt) % was -8883.91%. The lowest was -359900.00%. And the median was -12293.22%.

INDP's ROC (Joel Greenblatt) % is ranked worse than
91.29% of 1470 companies
in the Biotechnology industry
Industry Median: -338.875 vs INDP: -9038.63

Indaptus Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Indaptus Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Indaptus Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indaptus Therapeutics ROC (Joel Greenblatt) % Chart

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-359,900.00 -8,883.91 -11,740.94 -12,845.49

Indaptus Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17,578.49 -11,172.41 -6,145.05 -8,228.57 -9,037.84

Competitive Comparison of Indaptus Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Indaptus Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Indaptus Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's ROC (Joel Greenblatt) % falls into.



Indaptus Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.88) - (1.469 + 0 + 0.795)
=-1.384

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.633) - (1.459 + 0 + 1.213)
=-2.039

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Indaptus Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-16.72/( ( (0.196 + max(-1.384, 0)) + (0.174 + max(-2.039, 0)) )/ 2 )
=-16.72/( ( 0.196 + 0.174 )/ 2 )
=-16.72/0.185
=-9,037.84 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Indaptus Therapeutics  (NAS:INDP) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Indaptus Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Indaptus Therapeutics (Indaptus Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3 Columbus Circle, 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Executives
Glen R. Anderson 10 percent owner 3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman officer: Chief Medical Officer C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell director 4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev officer: Chief Medical Officer 13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman director, 10 percent owner, officer: Chief Scientific Officer C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert director 13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee director, 10 percent owner C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397